Extension Study of Drisapersen in DMD Subjects
An Open-label Extension Study of the Long-term Safety, Tolerability and Efficacy of Drisapersen in Subjects With Duchenne Muscular Dystrophy.
Sponsor: BioMarin Pharmaceutical
A observational or N/A phase clinical study on Duchenne Muscular Dystrophy, this trial is ongoing. The trial is conducted by BioMarin Pharmaceutical and has accumulated 11 data snapshots since 2026. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
No Longer Available
-
Sep 2024 — Sep 2025 [monthly]
No Longer Available
-
Jul 2024 — Sep 2024 [monthly]
No Longer Available
-
Jan 2021 — Jul 2024 [monthly]
No Longer Available
-
Sep 2020 — Jan 2021 [monthly]
No Longer Available
▶ Show 6 earlier versions
-
Jun 2018 — Sep 2020 [monthly]
No Longer Available
-
May 2018 — Jun 2018 [monthly]
No Longer Available
-
Apr 2018 — May 2018 [monthly]
No Longer Available
Phase: NA → None
-
Feb 2018 — Apr 2018 [monthly]
No Longer Available NA
Status: Terminated → No Longer Available · Phase: PHASE3 → NA
-
Feb 2017 — Feb 2018 [monthly]
Terminated PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- BioMarin Pharmaceutical
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ankara, Turkey (Türkiye) , Baltimore, United States , Barcelona, Spain , Bayern, Germany , Brno, Czechia , Brussels, Belgium , Buenos Aires, Argentina , Essen, Germany , Freiburg im Breisgau, Germany , Ghent, Belgium and 28 more locations